Onpattro (patisiran) slows neuropathy (nerve damage) progression in people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) who respond…
Articles by Andrea Lobo
The first participant has been dosed in a clinical trial evaluating the long-term effects of Attruby (acoramidis), an approved…
Long-term treatment with the experimental therapy candidate cliramitug safely and effectively reduces toxic clumps of the transthyretin (TTR) protein…
Long-term treatment with Amvuttra (vutrisiran) was found to be safe and to sustain disease stability in people with…
Long-term treatment with diflunisal may help slow disease progression in people with hereditary transthyretin amyloidosis (hATTR), according to a…
For East Asian adults with transthyretin amyloid cardiomyopathy (ATTR-CM), the approved therapy Amvuttra (vutrisiran) is a safe and…
Higher blood levels of fibroblast growth factor 23 (FGF23) — a bone-derived hormone — are associated with higher levels of…
Treatment with Wainua (eplontersen) was associated with slower disease progression and improved quality of life in both men and…
Amvuttra (vutrisiran) safely and effectively eases symptoms, reduces disability, and improves quality of life in East Asian adults with…
The U.S. Food and Drug Administration (FDA) has lifted its hold on a large-scale clinical trial evaluating nexiguran ziclumeran,…